TipRanks
EyePoint Pharmaceuticals Inc (EYPT)
NASDAQ:EYPT
US Market
EYPT
EyePoint Pharmaceuticals
RESEARCH TOOLSreports
Want to see EYPT full AI Analyst Report?

EyePoint Pharmaceuticals (EYPT) Stock Forecast & Price Target

1,121 Followers
See the Price Targets and Ratings of:

EYPT Analyst Ratings

Hold
13Ratings
Hold
3 Buy
9 Hold
1 Sell
Based on 13 analysts giving stock ratings to
EyePoint
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

EYPT Stock 12 Month Forecast

Average Price Target

$5.21
▲(4.49% Upside)
Based on 13 Wall Street analysts offering 12 month price targets for EyePoint Pharmaceuticals in the last 3 months. The average price target is $5.21 with a high forecast of $20.00 and a low forecast of $0.50. The average price target represents a 4.49% change from the last price of $4.99.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"$10","21":"$21","-1":"-$1","4.5":"$4.5","15.5":"$15.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.214285714285714,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$5.21</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$0.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,4.5,10,15.5,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.23,4.52,5.8100000000000005,7.1,8.39,9.68,10.97,12.260000000000002,13.55,14.84,16.13,17.42,18.71,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.23,3.3826373626373627,3.5352747252747254,3.687912087912088,3.8405494505494504,3.9931868131868136,4.145824175824176,4.298461538461538,4.451098901098901,4.603736263736264,4.756373626373627,4.909010989010989,5.061648351648352,{"y":5.214285714285714,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.23,3.02,2.81,2.6,2.39,2.1799999999999997,1.97,1.76,1.55,1.34,1.13,0.9199999999999999,0.71,{"y":0.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.915,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.09,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.26,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.27,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.29,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.34,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.02,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.34,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.15,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.195,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.25,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.58,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.23,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$20.00Average Price Target$5.21Lowest Price Target$0.50
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Mizuho Securities Analyst forecast on EYPT
Graig Suvannavejh
Mizuho Securities
Mizuho Securities
$39→$0.5
Hold
-89.98%
Downside
Downgraded
10/20/26
EyePoint downgraded to Neutral from Outperform at MizuhoEyePoint downgraded to Neutral from Outperform at Mizuho
Stifel Nicolaus Analyst forecast on EYPT
Annabel Samimy
Stifel Nicolaus
Stifel Nicolaus
$6
Buy
20.24%
Upside
Reiterated
10/20/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: EyePoint Pharmaceuticals (NASDAQ: EYPT) and Nyxoah (NASDAQ: NYXH)
J.P. Morgan Analyst forecast on EYPT
Tessa Romero
J.P. Morgan
J.P. Morgan
―
Sell
―
Downgraded
10/20/26
EyePoint downgraded to Underweight from Neutral at JPMorganEyePoint downgraded to Underweight from Neutral at JPMorgan
Citi Analyst forecast on EYPT
Yigal Nochomovitz
Citi
Citi
$17→$4
Buy
-19.84%
Downside
Reiterated
10/20/26
EyePoint price target lowered to $4 from $17 at CitiEyePoint price target lowered to $4 from $17 at Citi
RBC Capital Analyst forecast on EYPT
Lisa Walter
RBC Capital
RBC Capital
$5→$1
Hold
-79.96%
Downside
Reiterated
10/20/26
Analysts Offer Insights on Healthcare Companies: EyePoint Pharmaceuticals (NASDAQ: EYPT), Argenx Se (NASDAQ: ARGX) and UnitedHealth (NYSE: UNH)
H.C. Wainwright Analyst forecast on EYPT
Yi Chen
H.C. Wainwright
H.C. Wainwright
―
Hold
―
Reiterated
10/20/26
Yi Chen Reiterates Hold on EyePoint as DURAVYU Wet AMD Trial Disappoints and Focus Shifts to Long‑Dated DME Catalyst
Laidlaw Analyst forecast on EYPT
Yale Jen
Laidlaw
Laidlaw
―
Hold
―
Downgraded
10/20/26
EyePoint downgraded to Hold from Buy at LaidlawEyePoint downgraded to Hold from Buy at Laidlaw
Jefferies Analyst forecast on EYPT
Faisal Khurshid
Jefferies
Jefferies
$8→$1
Hold
-79.96%
Downside
Downgraded
10/19/26
EyePoint downgraded to Hold from Buy at JefferiesEyePoint downgraded to Hold from Buy at Jefferies
Guggenheim Analyst forecast on EYPT
Yatin Suneja
Guggenheim
Guggenheim
―
Hold
―
Downgraded
10/19/26
EyePoint downgraded to Neutral from Buy at GuggenheimEyePoint downgraded to Neutral from Buy at Guggenheim
Cantor Fitzgerald Analyst forecast on EYPT
Steven Seedhouse
Cantor Fitzgerald
Cantor Fitzgerald
―
Hold
―
Reiterated
10/19/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: EyePoint Pharmaceuticals (NASDAQ: EYPT), MannKind (NASDAQ: MNKD) and Disc Medicine (NASDAQ: IRON)
Chardan Capital Analyst forecast on EYPT
Andreas Argyrides
Chardan Capital
Chardan Capital
―
Hold
―
Reiterated
10/19/26
Chardan puts EyePoint target under review after trial missChardan puts EyePoint target under review after trial miss
JonesTrading Analyst forecast on EYPT
Debanjana Chatterjee
JonesTrading
JonesTrading
$20
Buy
300.80%
Upside
Reiterated
10/07/26
Duravyu: Buy Rating Reiterated as LUCIA Trial Seen as Key Catalyst, $20 Price Target Maintained
TD Cowen Analyst forecast on EYPT
Tara Bancroft
TD Cowen
TD Cowen
$20→$4
Hold
-19.84%
Downside
Downgraded
09/01/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Arcturus Therapeutics (NASDAQ: ARCT) and EyePoint Pharmaceuticals (NASDAQ: EYPT)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Mizuho Securities Analyst forecast on EYPT
Graig Suvannavejh
Mizuho Securities
Mizuho Securities
$39→$0.5
Hold
-89.98%
Downside
Downgraded
10/20/26
EyePoint downgraded to Neutral from Outperform at MizuhoEyePoint downgraded to Neutral from Outperform at Mizuho
Stifel Nicolaus Analyst forecast on EYPT
Annabel Samimy
Stifel Nicolaus
Stifel Nicolaus
$6
Buy
20.24%
Upside
Reiterated
10/20/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: EyePoint Pharmaceuticals (NASDAQ: EYPT) and Nyxoah (NASDAQ: NYXH)
J.P. Morgan Analyst forecast on EYPT
Tessa Romero
J.P. Morgan
J.P. Morgan
―
Sell
―
Downgraded
10/20/26
EyePoint downgraded to Underweight from Neutral at JPMorganEyePoint downgraded to Underweight from Neutral at JPMorgan
Citi Analyst forecast on EYPT
Yigal Nochomovitz
Citi
Citi
$17→$4
Buy
-19.84%
Downside
Reiterated
10/20/26
EyePoint price target lowered to $4 from $17 at CitiEyePoint price target lowered to $4 from $17 at Citi
RBC Capital Analyst forecast on EYPT
Lisa Walter
RBC Capital
RBC Capital
$5→$1
Hold
-79.96%
Downside
Reiterated
10/20/26
Analysts Offer Insights on Healthcare Companies: EyePoint Pharmaceuticals (NASDAQ: EYPT), Argenx Se (NASDAQ: ARGX) and UnitedHealth (NYSE: UNH)
H.C. Wainwright Analyst forecast on EYPT
Yi Chen
H.C. Wainwright
H.C. Wainwright
―
Hold
―
Reiterated
10/20/26
Yi Chen Reiterates Hold on EyePoint as DURAVYU Wet AMD Trial Disappoints and Focus Shifts to Long‑Dated DME Catalyst
Laidlaw Analyst forecast on EYPT
Yale Jen
Laidlaw
Laidlaw
―
Hold
―
Downgraded
10/20/26
EyePoint downgraded to Hold from Buy at LaidlawEyePoint downgraded to Hold from Buy at Laidlaw
Jefferies Analyst forecast on EYPT
Faisal Khurshid
Jefferies
Jefferies
$8→$1
Hold
-79.96%
Downside
Downgraded
10/19/26
EyePoint downgraded to Hold from Buy at JefferiesEyePoint downgraded to Hold from Buy at Jefferies
Guggenheim Analyst forecast on EYPT
Yatin Suneja
Guggenheim
Guggenheim
―
Hold
―
Downgraded
10/19/26
EyePoint downgraded to Neutral from Buy at GuggenheimEyePoint downgraded to Neutral from Buy at Guggenheim
Cantor Fitzgerald Analyst forecast on EYPT
Steven Seedhouse
Cantor Fitzgerald
Cantor Fitzgerald
―
Hold
―
Reiterated
10/19/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: EyePoint Pharmaceuticals (NASDAQ: EYPT), MannKind (NASDAQ: MNKD) and Disc Medicine (NASDAQ: IRON)
Chardan Capital Analyst forecast on EYPT
Andreas Argyrides
Chardan Capital
Chardan Capital
―
Hold
―
Reiterated
10/19/26
Chardan puts EyePoint target under review after trial missChardan puts EyePoint target under review after trial miss
JonesTrading Analyst forecast on EYPT
Debanjana Chatterjee
JonesTrading
JonesTrading
$20
Buy
300.80%
Upside
Reiterated
10/07/26
Duravyu: Buy Rating Reiterated as LUCIA Trial Seen as Key Catalyst, $20 Price Target Maintained
TD Cowen Analyst forecast on EYPT
Tara Bancroft
TD Cowen
TD Cowen
$20→$4
Hold
-19.84%
Downside
Downgraded
09/01/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Arcturus Therapeutics (NASDAQ: ARCT) and EyePoint Pharmaceuticals (NASDAQ: EYPT)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AMRXAmneal Pharmaceuticals
DNTHDianthus Therapeutics
ONCBeOne Medicines
IRLAIRulya Therapeutics
IDYAIDEAYA Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering EyePoint Pharmaceuticals

3 Months
Tessa RomeroJ.P. Morgan
Success Rate
2/6 ratings generated profit
33%
Average Return
+0.50%
Copying Tessa Romero's trades and holding each position for 3 Months would result in 33.33% of your transactions generating a profit, with an average return of +0.50% per trade.
1 Year
Debanjana ChatterjeeJonesTrading
Success Rate
8/20 ratings generated profit
40%
Average Return
-23.53%
Copying Debanjana Chatterjee's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of -23.53% per trade.
2 Years
Tessa RomeroJ.P. Morgan
Success Rate
2/6 ratings generated profit
33%
Average Return
-12.43%
Copying Tessa Romero's trades and holding each position for 2 Years would result in 33.33% of your transactions generating a profit, with an average return of -12.43% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

EYPT Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
14
22
28
22
17
Buy
1
1
0
0
0
Hold
0
0
5
6
14
Sell
0
0
0
0
1
Strong Sell
0
0
0
0
0
total
15
23
33
28
32
In the current month, EYPT has received 17 Buy Ratings, 14 Hold Ratings, and 1 Sell Ratings. EYPT average Analyst price target in the past 3 months is 5.21.
Each month's total comprises the sum of three months' worth of ratings.

EYPT Financial Forecast

EYPT Earnings Forecast

Next quarter’s earnings estimate for EYPT is -$0.93 with a range of -$1.19 to -$0.79. The previous quarter’s EPS was -$1.09. EYPT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year EYPT has Performed in-line its overall industry.
Next quarter’s earnings estimate for EYPT is -$0.93 with a range of -$1.19 to -$0.79. The previous quarter’s EPS was -$1.09. EYPT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year EYPT has Performed in-line its overall industry.

EYPT Sales Forecast

Next quarter’s sales forecast for EYPT is $231.00K with a range of $0.00 to $575.00K. The previous quarter’s sales results were $507.00K. EYPT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year EYPT has Performed in-line its overall industry.
Next quarter’s sales forecast for EYPT is $231.00K with a range of $0.00 to $575.00K. The previous quarter’s sales results were $507.00K. EYPT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year EYPT has Performed in-line its overall industry.

EYPT Stock Forecast FAQ

What is EYPT’s average 12-month price target, according to analysts?
Based on analyst ratings, EyePoint Pharmaceuticals Inc’s 12-month average price target is 5.21.
    What is EYPT’s upside potential, based on the analysts’ average price target?
    EyePoint Pharmaceuticals Inc has 4.49% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is EYPT a Buy, Sell or Hold?
          EyePoint Pharmaceuticals Inc has a consensus rating of Hold which is based on 3 buy ratings, 9 hold ratings and 1 sell ratings.
            What is EyePoint Pharmaceuticals Inc’s price target?
            The average price target for EyePoint Pharmaceuticals Inc is 5.21. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $20.00 ,the lowest forecast is $0.50. The average price target represents 4.49% Increase from the current price of $4.99.
              What do analysts say about EyePoint Pharmaceuticals Inc?
              EyePoint Pharmaceuticals Inc’s analyst rating consensus is a Hold. This is based on the ratings of 13 Wall Streets Analysts.
                How can I buy shares of EYPT?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.